NCE-1 Intelligence & Market Opportunity

Truqap

Capivasertib

Anticancer

Tablet

Truqap is used with fulvestrant to treat certain advanced breast cancers with specific genetic mutations. It works by blocking the AKT pathway, which helps control tumor cell survival and growth.

Approval Date

16-Nov-23

NCE-1 Date

16-Nov-27

NCE Date

16-Nov-28

Commercial snapshot

Market performance & projections

Revenue ($M)

728

CAGR (%)

0.2097

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

967

2027

1193

2028

1409

2029

1559

2030

1699

2031

1821

2032

1935

Molecule profile

Details & specifications

Molecule

Capivasertib

Innovator

ASTRAZENECA PHARMACEUTICALS LP

Dosage Form

Tablet

Strength

160 mg and 200 mg

Therapeutic Category

Anticancer

Usage

To treat breast cancer that meets certain disease criteria

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.